SYNthesis Med Chem

Founded in 2018 and headquartered in Cambridge, UK, SYNthesis Med Chem is a chemistry-focused CRO offering a 'Best of Both Worlds' service model. It combines medicinal chemistry expertise from scientists in the UK, USA, Canada, and Australia with large-scale synthetic chemistry operations in China, employing over 500 chemists. As part of Viva Biotech, it provides end-to-end services from hit discovery to clinical candidate nomination for biotech and pharma clients. The company is a private, revenue-generating services firm without its own therapeutic pipeline.

Integrated drug discovery service model combining Western medicinal chemistry design with cost-effective synthetic chemistry execution in China. Specializes in complex modalities including PROTACs, molecular glues, and ADC linker-payloads.

SYNthesis competes in the crowded drug discovery CRO space against giants like WuXi AppTec, Charles River, and Labcorp, as well as numerous specialized chemistry firms. Its differentiation lies in its specific 'Best of Both Worlds' hybrid geographic model and its focused expertise in cutting-edge modalities like protein degradation, which may not be a core strength of larger, more generalized competitors.